针对用于癌症免疫治疗的T细胞参与剂的创新策略
Cristina Bergamaschi1, Miguel Gaspar2, Thomas Ciucci1
1Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
mAbs
|July 11, 2025
概括
下一代T细胞参与剂 (TCEs) 通过提高安全性和疗效,提供了改进的癌症免疫疗法. 在TCE设计的创新旨在克服诸如细胞因子释放综合征和瘤免疫抑制等挑战,以获得更广泛的患者利益.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 致癌细胞 (TCEs) 是癌症免疫疗法的重大进步,它将T细胞重定向以消除瘤细胞.
- 目前的TCE应用面临的局限性包括细胞因子释放综合征 (CRS),点外瘤毒性,以及克服各种癌症类型的瘤免疫抑制.
研究的目的:
- 本综述审查了TCE设计的最新创新,重点是提高安全性和治疗疗效.
- 目标是探索减轻当前临床挑战的策略,并扩大TCE的实用性.
主要方法:
- 讨论的创新包括优化TCE几何结构以形成免疫突触,以及微调抗CD3/TCR域亲和力以减少CRS.
- 逻辑关闭的方法,如双重准和瘤微环境因素的条件激活,正在探索,以尽量减少瘤外毒性.
- 审查还考虑了整合辅助刺激信号来提高疗效.
主要成果:
- 优化的设计和逻辑关闭的策略显示出降低CRS和点外瘤毒性的潜力.
- 这些进展可能会导致在血液和固体瘤中产生更深,更持久的反应.
- 利用辅助刺激信号可以进一步提高治疗的有效性.
结论:
- 下一代TCE有望克服当前治疗方法的局限性,扩大其治疗窗口,并使组合治疗成为可能.
- 预计TCEs将成为癌症免疫治疗的基本要素,为更广泛的患者群体改善治疗结果.
相关概念视频
Tumor Immunotherapy
665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
Cancer Vaccines
517
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
517
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Cytotoxic T Cells-mediated Immune Response
2.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.4K
T Cell Activation and Clonal Selection
5.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
5.5K


